Thursday, April 11, 2019 1:10:24 PM
... This does need a lot of work, I know.
A 2015 post from blanka highlighting the brilliant minds pushing Anavex forward.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=119221094
Alzheimer’s and Parkinson’s Disease: Similarities and Differences (Aarsland and Weintraub have AVXL affiliation)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147932208
Penny double quoted this 2016 PR from the company:
___________________________________________________________________________________________________________________
Christopher Missling:
Missling's unique skill set(from Bourbon_on_my_cornflakes) :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147033809
Missling 2017 research posted on researchgate.net
https://www.researchgate.net/profile/Christopher_Missling
___________________________________________________________________________________________________________________
Walter E Kaufmann:
Appointment of Walter E Kaufmann, MD as Chief Medical Officer
https://www.anavex.com/anavex-life-sciences-announces-the-appointment-of-walter-e-kaufmann-md-as-chief-medical-officer/
Info on Dr. Kaufmann who will be running the 2-73 Rett Syndrome trial and who is now CMO for Anavex:
http://gcbcenter.kennedykrieger.org/staff.jsp
___________________________________________________________________________________________________________________
Emmanuel O (“Tayo”) Fadiran:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147996796
___________________________________________________________________________________________________________________
Dag Aarsland:
November 2018 - New SAB member Dr. Dag Aarsland, support for current and future pipeline:
https://globenewswire.com/news-release/2018/11/08/1647793/0/en/Anavex-Life-Sciences-Strengthens-its-Scientific-Advisory-Board-with-Distinguished-Researcher-for-Clinical-Treatment-of-Parkinson-s-Disease-Dementia-PDD.html
Eisai is connected with one of Anavex scientific advisors. (Dag Aarsland ) in Lisbon.
Thursday, March 28th, 17:20 - 19:20, Auditorium VI+VII
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147789180
___________________________________________________________________________________________________________________
Rudolph Tanzi:
Fortunately, Anavex leadership has world wide prominence:
PBS quoting Tanzi (thanks to Kevli33):
https://www.pbs.org/newshour/health/why-the-number-of-americans-with-alzheimers-could-more-than-double-by-2050
___________________________________________________________________________________________________________________
Stephen Toutain:
Stephan Toutain appointed Senior Vice President of Operations and Claus van der Velden to Board of Directors
https://www.anavex.com/anavex-life-sciences-strengthens-management-team-board-directors/
Toutain's linked in profile lists expanded access
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147884394
Toutain DD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147172095
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146739245
___________________________________________________________________________________________________________________
Daniel Weintraub:
Anavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer
https://globenewswire.com/news-release/2019/01/02/1679430/0/en/Anavex-Life-Sciences-Announces-the-Appointment-of-Walter-E-Kaufmann-MD-as-Chief-Medical-Officer.html
http://genetics.emory.edu/faculty/adjunct/kaufmann-walter.html
___________________________________________________________________________________________________________________
Daniel Klamer, MS,PHD,MBA:
From Anavex home page:
February 19-21, 2019, Anavex participated in the 7th World CNS Summit - Targeting Neurodegenerative Diseases.
https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/?tab=agenda
From the event’s description:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144414392';
Klamer paper on the topic above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147056161
See patent section for new info on patents for pain and Alzheimer's treatment protocol.
___________________________________________________________________________________________________________________
Alexandre Vamvakides:
https://www.anavex.com/anavex-life-sciences-corp-acquires-a-portfolio-of-patents-and-appoints-dr-alexandre-vamvakides-as-cso-and-director/
___________________________________________________________________________________________________________________
Tangui Maurice:
Tangui Maurice was co-developer of 2-73
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=128848083
2011 "ANAVEX 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice"
“It may be that Akt increase and GSK-3beta decrease is a protective mechanism in AD and is restored by mixed sigma-1 and muscarinic agents such as ANAVEX 2-73,” said Dr. Tangui Maurice, PhD, CNRS Research Director, Team II Endogenous Neuroprotection in Neurodegenerative Diseases INSERM, University of Montpellier, one of the poster authors and a member of the Anavex Scientific Advisory Board. “For the very first time, these data show these mixed sigma and muscarinic agents, such as ANAVEX 2-73, block both amyloid-related toxicity and tau protein-related pathology.”
https://www.anavex.com/anavex-presents-data-on-potential-dual-utility-of-anavex-2-73-in-both-amyloid-and-tau-pathology/
Monday, July 16, 2012
Time: 1 p.m. to 3:30 p.m.
Title: Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer's disease: Analyses of administration schedules and combination studies with donepezil and memantine
Poster #: 30647
https://www.biospace.com/article/anavex-life-sciences-corp-to-present-at-alzheimer-s-association-international-conference-
2013 positive preclinical data
Tangui Maurice, PhD, said, “These observations suggest that ANAVEX 2-73 induces a strong neuroprotective effect that is apparently amyloid-beta independent. The data also confirms the efficacy of the mixed muscarinic cholinergic and sigma-1 receptor agonist in a chronic transgenic mouse model of Alzheimer’s. The compound may enable effective brain protection during the most aggressive phase of the disease pathology.”
https://www.anavex.com/anavex-announces-positive-data-for-anavex-2-73-in-alzheimers-disease/
Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208
Board Post on recent paper by Tangui Maurice
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147955142
___________________________________________________________________________________________________________________
Paul Aisen:
Anavex, ACTC and Paul Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089981
Bloomberg board links for Paul Aisen:
https://www.bloomberg.com/research/stocks/people/relationship.asp?personId=20759834&ticker=AVXL&previousCapId=26606238&previousTitle=OrgSyn%2520Laboratory%252C%2520Inc.
Aisen is a director of the ACTC also -
https://act-ad.org/about-act-ad/science-advisory-board/
March 2019 discussion of ACTC begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409548
Historical discussions about Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148133076
PR appointing Aisen to SAB in 2011:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147411285
See the bottom of this post on Aisen board links:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147360088
Aisen and the ACTC:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409564
Aisen working on accelerating recruitment in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144345752
ACTC Ops Plan with the initial focus at USC with Dr Paul Aisen's group. (from Talon38 8/18 post)
http://grantome.com/grant/NIH/U24-AG057437-01
___________________________________________________________________________________________________________________
Alani Selvy:
New hire noted by kevli33 - no public info from the company as of 04/05/19
https://www.linkedin.com/in/alani-selvey-9117897/?trk=org-employees_mini-profile_title
https://www.researchgate.net/profile/Alani_Selvey
___________________________________________________________________________________________________________________
SAB and BOD:
*** note to self - break this up into sections
___________________________________________________________________________________________________________________
Harald Hampel:
Research Gate intro:
https://www.researchgate.net/profile/Harald_Hampel
HH twitter:
https://twitter.com/harald_hampel#
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147429124
Revolution of Alzheimer Precision Neurology: Passageway of Systems Biology and Neurophysiology
Harald Hampel primary author, posted by nidan7500
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008221/#!po=0.337838
___________________________________________________________________________________________________________________
Claus van der Velden:
Claus van der Velden appointed to Board of Directors
https://www.anavex.com/anavex-life-sciences-strengthens-management-team-board-directors/
___________________________________________________________________________________________________________________
Andrew J. Cole:
PennyDouble reminds us, we have an expert on the SAB :
"Dr. Andrew J. Cole is Director of the MGH Epilepsy Service, Chief of the Division of Clinical Neurophysiology and Epilepsy and Professor of Neurology at Harvard Medical School."
https://www.anavex.com/anavex-life-sciences-appoints-distinguished-researcher-neurology-epilepsy-scientific-advisory-board/
The significance of adding Dr Andrew Cole MD authority on Epilepsy to Anavex SAB:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144358640
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM